Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | -1.31% | -1.63% | -6.52% |
04-30 | B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
04-29 | HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.52% | 216M | |
+3.81% | 108B | |
+11.14% | 104B | |
+1.28% | 22.33B | |
-12.86% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.63% | 17.64B | |
+3.77% | 14.05B | |
+37.32% | 12.51B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- Ligand Acquires 13% Stake in Ovid Therapeutics' Soticlestat Royalties for $30 Million